Gablofen Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $203M

Gablofen General Information

Description

Manufacturer of drugs intended to offer medicines for spasticity and pain management. The company offers drugs that treat side effects such as muscle tightness, spasms, fatigue, and frozen and stiff joints.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 332 North Minnesota
  • Street W1750
  • Saint Paul, MN 55101
  • United States
+1 (800)
Primary Industry
Pharmaceuticals
Parent Company
Vertical(s)
Corporate Office
  • 332 North Minnesota
  • Street W1750
  • Saint Paul, MN 55101
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gablofen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 20-Mar-2017 $203M Completed Generating Revenue
6. Merger/Acquisition 03-Oct-2012 Completed Generating Revenue
5. Early Stage VC 27-Apr-2011 Completed Generating Revenue
4. Grant 01-Jan-2010 Completed Generating Revenue
3. Early Stage VC 18-Aug-2009 Completed Generating Revenue
2. Early Stage VC (Series B) 26-Jun-2008 $6M $8M Completed Generating Revenue
1. Early Stage VC (Series A) $2M $2M Completed Generating Revenue
To view Gablofen’s complete valuation and funding history, request access »

Gablofen Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
InterWest Health Partners Corporate Venture Capital Minority
InterWest Partners Venture Capital Minority
Mallinckrodt Pharmaceuticals Corporation Majority
Michael J. Fox Foundation Limited Partner
Thomas McNerney & Partners Venture Capital Minority
To view Gablofen’s complete investors history, request access »

Gablofen FAQs

  • When was Gablofen founded?

    Gablofen was founded in 2007.

  • Where is Gablofen headquartered?

    Gablofen is headquartered in Saint Paul, MN.

  • What industry is Gablofen in?

    Gablofen’s primary industry is Pharmaceuticals.

  • Is Gablofen a private or public company?

    Gablofen is a Private company.

  • What is the current valuation of Gablofen?

    The current valuation of Gablofen is .

  • What is Gablofen’s current revenue?

    The current revenue for Gablofen is .

  • How much funding has Gablofen raised over time?

    Gablofen has raised $18.1M.

  • Who are Gablofen’s investors?

    InterWest Health Partners, InterWest Partners, Mallinckrodt Pharmaceuticals, Michael J. Fox Foundation, and Thomas McNerney & Partners have invested in Gablofen.

  • When was Gablofen acquired?

    Gablofen was acquired on 20-Mar-2017.

  • Who acquired Gablofen?

    Gablofen was acquired by Piramal Enterprises.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process